Global Alzheimer's and dementia research initiatives

Efforts to advance Alzheimer's disease and dementia prevention are expanding through diverse scientific, clinical, and regulatory initiatives across several countries.

In Germany, funding has been allocated to projects investigating the impact of intergenerational outdoor activities on well-being and the relationship between blood lipid changes and genetic Alzheimer's. In the United States, the ARPA-H agency is investing up to 41 million dollars into a multi-institutional platform trial to test combinations of existing drugs and natural products for preventive therapeutic pathways.

Further developments include a nurse-led intervention program in Australia using the HAPPI MIND app, which demonstrated improvements in dementia risk profiles through lifestyle changes. Additionally, the U.S. Food and Drug Administration (FDA) has established the Alzheimer’s Prevention Accelerator to address challenges in developing drugs that halt neurodegeneration before clinical symptoms appear, focusing on innovative clinical trial designs and the integration of biomarkers and digital health technologies.